XBIO Xenetic Biosciences Inc.

1.53
-0.03  -2%
Previous Close 1.56
Open 1.57
Price To Book 0.55
Market Cap 8,805,366
Shares 5,755,141
Volume 741,232
Short Ratio
Av. Daily Volume 574,095
Stock charts supplied by TradingView

NewsSee all news

  1. Xenetic Biosciences, Inc. Announces Publication of Data from Partner's Phase 1/2 Study Evaluating Program Leveraging Polyxen(R) Platform Technology

    - SHP656 program utilized Xenetic's PolyXen platform technology to conjugate polysialic acid to therapeutic blood-clotting factors - Phase 1/2 study demonstrated SHP656's efficacy and pharmacokinetic data

  2. Xenetic Biosciences, Inc. Reports Third Quarter 2019 Financial Results and Provides Corporate Update

    - Company ramps up activities to execute XCART's preclinical and regulatory strategy -- Cash runway expected to fund Company through preclinical advancements towards IND filing -FRAMINGHAM, MA / ACCESSWIRE / November

  3. Xenetic Biosciences, Inc. Provides Business Outlook

    Recent completion of acquisition of innovative CAR T technology platform (XCART) has the potential to drive significant value for shareholders Management working with KOLs and subject matter experts to formalize XCART

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 enrolment closed in March 2019 due to slow enrolment.
XBIO-101
Endometrial cancer

Latest News

  1. Xenetic Biosciences, Inc. Announces Publication of Data from Partner's Phase 1/2 Study Evaluating Program Leveraging Polyxen(R) Platform Technology

    - SHP656 program utilized Xenetic's PolyXen platform technology to conjugate polysialic acid to therapeutic blood-clotting factors - Phase 1/2 study demonstrated SHP656's efficacy and pharmacokinetic data

  2. Xenetic Biosciences, Inc. Reports Third Quarter 2019 Financial Results and Provides Corporate Update

    - Company ramps up activities to execute XCART's preclinical and regulatory strategy -- Cash runway expected to fund Company through preclinical advancements towards IND filing -FRAMINGHAM, MA / ACCESSWIRE / November

  3. Xenetic Biosciences, Inc. Provides Business Outlook

    Recent completion of acquisition of innovative CAR T technology platform (XCART) has the potential to drive significant value for shareholders Management working with KOLs and subject matter experts to formalize XCART